Current Vascular Pharmacology
Title:Preface
Volume: 11 Issue: 1
Author(s): D.P. Mikhailidis
Affiliation:
Export Options
About this article
Cite this article as:
Mikhailidis D.P., Preface, Current Vascular Pharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570161111309010001
DOI https://dx.doi.org/10.2174/1570161111309010001 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacomimetics of Exercise: Novel Approaches for Hippocampally- Targeted Neuroprotective Agents
Current Medicinal Chemistry Editorial (Thematic Issue: Experimental Pharmacological Targets for the Treatment of Cardiac Arrhythmias: Beyond the Vaughn-Williams Classification)
Current Medicinal Chemistry Cellular Prion and its Catabolites in the Brain: Production and Function
Current Molecular Medicine Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption?
Current Alzheimer Research Outcome-Dependent Global Similarity Analysis of Imbalanced Core Signaling Pathways in Ischemic Mouse Hippocampus
CNS & Neurological Disorders - Drug Targets Preface
Drug Metabolism Letters Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Disaster Psychiatry: Good Intentions Seeking Science and Sustainability
Adolescent Psychiatry Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
Current Vascular Pharmacology Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Application of Robot to Hand Function Rehabilitation
Recent Patents on Mechanical Engineering Medicinal Plants Towards Modeling Skin Cancer
Current Drug Targets Pharmacological Modulations of the Renin-Angiotensin-Aldosterone System in Human Congestive Heart Failure: Effects on Peripheral Vascular Endothelial Function
Current Vascular Pharmacology Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Aripiprazole Overdose and Transient 2:1 Second Degree Atrioventricular Block: Only A Coincidence?
Current Drug Safety Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms
Current Neuropharmacology Gas Bioengineering Using Hemoglobin-Vesicles For Versatile Clinical Applications
Current Pharmaceutical Design Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Current Vascular Pharmacology Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets Development and Characterization of Amphotericin B Loaded Solid Lipid Nanoparticles Against Experimental Visceral Leishmaniasis
Pharmaceutical Nanotechnology